This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.83% per year. These returns cover a period from January 1, 1988 through January 5, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
medical: Archive
PLSE Shares Positive First-in-Human nPulse Cardiac Catheter Data
by Zacks Equity Research
Pulse Biosciences shares late-breaking AF data showing up to 100% procedural success, fast procedures and low adverse events for nPulse.
ISRGPositive Net Change MASINegative Net Change VCYTPositive Net Change PLSEPositive Net Change
medical medical-devices
Add These 4 GARP Stocks to Your Portfolio to Receive Handsome Returns
by Zacks Equity Research
The GARP strategy helps investors gain exposure to stocks that have solid prospects and are trading at a discount. APH, GE, RMD and AMP are some such stocks.
GENegative Net Change APHPositive Net Change AMPNegative Net Change RMDPositive Net Change
aerospace artificial-intelligence finance medical tech-stocks
GEHC Strengthens AI Fetal Ultrasound via Diagnoly Collaboration
by Zacks Equity Research
GE HealthCare and Diagnoly unite to embed AI fetal screening in Voluson ultrasounds, expanding FDA-cleared tools to drive software-led growth and differentiation.
BSXNegative Net Change ATRCNegative Net Change VCYTPositive Net Change GEHCNegative Net Change
medical medical-devices
BD Stock Dips in Pre-Market Despite Q1 Earnings Beat, Margins Up
by Zacks Equity Research
BDX posts an earnings beat with revenue growth and expanding margins in first-quarter fiscal 2026 quarter, though adjusted profit declined year over year.
BDXNegative Net Change DVANegative Net Change CAHPositive Net Change DOCSNegative Net Change
earnings medical medical-devices
BMY Up 7.6% Post Q4 Earnings: Should You Buy, Sell or Hold the Stock?
by Ekta Bagri
BMY jumps after strong Q4 2025 results as its growth portfolio drives beats, lifts sentiment and offsets generic pressure on legacy drugs.
BMYNegative Net Change PFENegative Net Change MRKNegative Net Change BNTXPositive Net Change
biotechnology biotechs medical pharmaceuticals
WST Q4 Earnings Preview: Can HVP Momentum Continue to Drive Margins?
by Zacks Equity Research
West Pharmaceutical heads into Q4 with HVP demand likely lifting margins, but tariff risk looms as revenue and EPS targets come into focus.
MASINegative Net Change DXCMNegative Net Change MMSINegative Net Change WSTPositive Net Change
medical medical-devices
Zoetis Gears Up to Report Q4 Earnings: Here's What to Expect
by Zacks Equity Research
ZTS is set up for Q4 earnings beat, fueled by strong international companion animal products sales, even as weaker U.S. demand weighs on results.
MRNAPositive Net Change ZTSNegative Net Change CRSPPositive Net Change CSTLNegative Net Change
biotechnology biotechs medical pharmaceuticals
Novo Nordisk Stock Whipsawed by GLP-1 Pill Fears: Relief Ahead?
by Ahan Chakraborty
NVO shares swing sharply after fears over cheap compounded GLP-1 pills, before FDA action and a Hims retreat spark a sharp rebound.
NVOPositive Net Change LLYNegative Net Change VKTXPositive Net Change HIMSNegative Net Change
biotechnology biotechs medical pharmaceuticals
Strength in Cardiovascular Unit Likely to Lift MDT's Q3 Performance
by Zacks Equity Research
Medtronic's Q3 outlook hinges on strong Cardiovascular momentum, with revenues projected to be up 7.3% year over year despite softer EPS.
MDTNegative Net Change MMSINegative Net Change GMEDNegative Net Change VCYTPositive Net Change
earnings medical medical-devices
Moderna to Report Q4 Earnings: Is a Beat in Store for the Stock?
by Zacks Equity Research
MRNA is set to report Q4 results on Feb. 13, with expectations for an earnings beat as COVID vaccine sales and pipeline updates stay in focus.
MRKNegative Net Change MRNAPositive Net Change JAZZNegative Net Change CSTLNegative Net Change
biotechs medical messenger-rna pharmaceuticals vaccines